T1	Pharmacological_substance 0 12	Tirapazamine
N1000 	Reference T1 MeSH:C049947	Tirapazamine
T2	Pharmacological_substance 18 27	cisplatin
N1001 	Reference T2 MeSH:D002945	cisplatin
T3	Pharmacological_substance 35 44	cisplatin
N1002 	Reference T3 MeSH:D002945	cisplatin
T4	Disorder 48 83	advanced non-small-cell lung cancer
T5	Pharmacological_substance 139 148	Cisplatin
N1003 	Reference T5 MeSH:D002945	Cisplatin
T6	Pharmacological_substance 153 165	Tirapazamine
N1004 	Reference T6 MeSH:C049947	Tirapazamine
T8	Pharmacological_substance 260 269	Cisplatin
N1005 	Reference T8 MeSH:D002945	Cisplatin
T9	Pharmacological_substance 274 286	Tirapazamine
N1006 	Reference T9 MeSH:C049947	Tirapazamine
T10	Disorder 304 360	Advanced Previously Untreated Non-Small-Cell Lung Tumors
T12	Pharmacological_substance 428 440	tirapazamine
N1007 	Reference T12 MeSH:C049947	tirapazamine
T13	Pharmacological_substance 446 455	cisplatin
N1008 	Reference T13 MeSH:D002945	cisplatin
T14	Disorder 477 503	non-small-cell lung cancer
N1 	Reference T14 UMLS:C0007131	non-small-cell lung cancer
T15	Disorder 505 510	NSCLC
N2 	Reference T15 UMLS:C0007131	NSCLC
T16	Disorder 548 553	NSCLC
N3 	Reference T16 UMLS:C0007131	NSCLC
T17	Pharmacological_substance 588 600	tirapazamine
N1009 	Reference T17 MeSH:C049947	tirapazamine
T21	Pharmacological_substance 661 670	cisplatin
N1010 	Reference T21 MeSH:D002945	cisplatin
T24	Pharmacological_substance 713 722	cisplatin
N1011 	Reference T24 MeSH:D002945	cisplatin
T25	Disorder 804 809	NSCLC
N4 	Reference T25 UMLS:C0007131	NSCLC
T27	Disorder 843 860	pleural effusions
N5 	Reference T27 UMLS:C0032227	pleural effusions
T36	Pharmacological_substance 1264 1276	tirapazamine
N1012 	Reference T36 MeSH:C049947	tirapazamine
T37	Pharmacological_substance 1282 1291	cisplatin
N1013 	Reference T37 MeSH:D002945	cisplatin
T39	Pharmacological_substance 1330 1339	cisplatin
N1014 	Reference T39 MeSH:D002945	cisplatin
T40	Pharmacological_substance 1379 1388	cisplatin
N1015 	Reference T40 MeSH:D002945	cisplatin
T41	Disorder 1478 1490	hearing loss
N6 	Reference T41 UMLS:C1384666	hearing loss
T42	Disorder 1534 1542	diarrhea
N7 	Reference T42 UMLS:C0011991	diarrhea
T43	Disorder 1544 1553	skin rash
N8 	Reference T43 UMLS:C0015230	skin rash
T44	Disorder 1555 1561	nausea
N9 	Reference T44 UMLS:C0027497	nausea
T45	Disorder 1567 1575	vomiting
N10 	Reference T45 UMLS:C0042963	vomiting
T46	Disorder 1616 1632	myelosuppression
N11 	Reference T46 UMLS:C0854467	myelosuppression
T47	Disorder 1634 1655	peripheral neuropathy
N12 	Reference T47 UMLS:C0031117	peripheral neuropathy
T48	Disorder 1679 1695	cardiac toxicity
T49	Disorder 1703 1709	deaths
N13 	Reference T49 UMLS:C1306577	deaths
T50	Pharmacological_substance 1721 1733	tirapazamine
N1016 	Reference T50 MeSH:C049947	tirapazamine
T51	Pharmacological_substance 1767 1779	tirapazamine
N1017 	Reference T51 MeSH:C049947	tirapazamine
T52	Pharmacological_substance 1805 1814	cisplatin
N1018 	Reference T52 MeSH:D002945	cisplatin
T53	Disorder 1832 1846	advanced NSCLC
N14 	Reference T53 UMLS:C0007131	advanced NSCLC
T54	Disorder 1865 1872	hypoxia
N15 	Reference T54 UMLS:C0242184	hypoxia
T55	Disorder 1919 1931	malignancies
N16 	Reference T55 UMLS:C0006826	malignancies
T59	Subject 786 798	446 patients
T11	Disorder 183 239	Advanced Previously Untreated Non-Small-Cell Lung Tumors
T18	Subject 169 177	Subjects
T20	Subject 513 521	Patients
T29	Subject 1028 1042	Sixty patients
T30	Disorder 1071 1087	brain metastases
N17 	Reference T30 UMLS:C0220650	brain metastases
T35	Pharmacological_substance 1361 1373	tirapazamine
N1019 	Reference T35 MeSH:C049947	tirapazamine
T60	Disorder 1434 1448	adverse events
T61	Disorder 1517 1532	muscle cramping
N18 	Reference T61 UMLS:C0026821	muscle cramping
T62	Disorder 1660 1665;1687 1695	renal toxicity
N19 	Reference T62 UMLS:C0595916	renal toxicity
T63	Disorder 1667 1674;1687 1695	hepatic toxicity
N20 	Reference T63 UMLS:C0348754	hepatic toxicity
T64	Subject 1913 1918	human
T65	Subject 1818 1826	patients
T70	Subject 290 298	Subjects
T28	Negation_cue 1588 1590	no
T34	Speculation_cue 391 400	determine
T71	Manner_cue 1417 1433	mild to moderate
T7	Combination 13 17	plus
T19	Combination 441 445	plus
T23	Combination 636 644	followed
T33	Combination 1277 1281	plus
T57	Combination 1374 1378	plus
T31	Combination 270 273	and
T56	Combination 149 152	and
T68	Combination 1793 1801	activity
